An Open label Clinical study to evaluate the efficacy and safety of B C CAPS manufactured by NUTRA GRACE in Abnormal vaginal discharge due to microbial infections

TRA GRACE0 个研究点目标入组 15 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Age 18- 45 yrs
•2. Subjects with presence of signs and symptoms such as irritation, soreness, dysuria, vulvovaginal inflammation (edema, erythema) and abdominal pain.
•3. Subjects with confirmed laboratory diagnosis of abnormal vaginal discharge.
•4. Subjects willing to give written informed consent and come for a regular follow up

•1. Allergy to neem products.
•2. Pregnant subjects.
•3. Patients who had taken oral or intravenous antifungal agents within 4weeks or used topical vaginal antifungal drugs within 1 week before enrollment.
•4. Terminally ill patients or patients with severe cardiac, hepatic renal or cerebrovascular disease, malignancy, chronic uncon-trolled systemic disease e.g. hypertension, collagen disorders, etc or any other serious medical illness.
•5. Patients who have participated in a new drug study in the past 3 months.
•6. Any other condition that in the opinion of the investigator does not justify the patientâ??s participation in the study.

发起方

TRA GRACE